Amgen And Genentech, Inc. Ink Licensing Pact On Technology

NEW YORK, Jan 26 (Reuters) - Amgen (AMGN.O: Quote, Profile, Research) and Genentech Inc. (DNA.N: Quote, Profile, Research) on Thursday said they have entered into license agreements that give each company access to multiple patents relating to the manufacture and use of antibodies and related technology.

MORE ON THIS TOPIC